Lymphopenia combined with low TCR diversity (divpenia) predicts poor overall survival in metastatic breast cancer patients
暂无分享,去创建一个
J. Blay | J. Pierga | I. Ray-Coquard | C. Caux | O. Trédan | T. Bachelot | D. Pérol | S. Chabaud | P. Heudel | C. Ménétrier-Caux | Manuarii Manuel | Solène Perez | A. Courtier | N. Pasqual | G. Clapisson | I. Labidi-Galy | J. Mouret | G. Parmentier | A. Grivès | T. Rabeony
[1] M. Morre,et al. Interleukin-7 and immune reconstitution in cancer patients: a new paradigm for dramatically increasing overall survival , 2012, Targeted Oncology.
[2] D. Klatzmann,et al. Half of the T‐cell repertoire combinatorial diversity is genetically determined in humans and humanized mice , 2012, European journal of immunology.
[3] J. Blay,et al. Early detection of tumor cells by innate immune cells leads to T(reg) recruitment through CCL22 production by tumor cells. , 2011, Cancer research.
[4] J. Blay,et al. Quantitative and functional alterations of plasmacytoid dendritic cells contribute to immune tolerance in ovarian cancer. , 2011, Cancer research.
[5] Ian O Ellis,et al. Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] J. Castillo,et al. Lymphopenia and breast cancer subtypes as prognostic factors in patients with locally advanced breast cancer. , 2011, Journal of Clinical Oncology.
[7] Yuan Zhang,et al. Normalization of T cell receptor repertoire diversity in patients with advanced colorectal cancer who responded to chemotherapy , 2011, Cancer science.
[8] G. Thibault,et al. Pre-treatment lymphopenia as a prognostic biomarker in colorectal cancer patients receiving chemotherapy , 2011, Cancer Chemotherapy and Pharmacology.
[9] J. Wolchok,et al. Anti-CTLA-4 antibody therapy: immune monitoring during clinical development of a novel immunotherapy. , 2010, Seminars in oncology.
[10] P. Natali,et al. Dacarbazine treatment before peptide vaccination enlarges T-cell repertoire diversity of melan-a-specific, tumor-reactive CTL in melanoma patients. , 2010, Cancer research.
[11] D. Schadendorf,et al. Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.
[12] S. Maiella,et al. In vivo expansion of naive and activated CD4+CD25+FOXP3+ regulatory T cell populations in interleukin-2–treated HIV patients , 2010, Proceedings of the National Academy of Sciences.
[13] D. Klatzmann,et al. High diversity of the immune repertoire in humanized NOD.SCID.γc−/− mice , 2009, European journal of immunology.
[14] J. Blay,et al. Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas, and lymphomas. , 2009, Cancer research.
[15] C. Rouzioux,et al. Enhanced T cell recovery in HIV-1-infected adults through IL-7 treatment. , 2009, The Journal of clinical investigation.
[16] J. Blay,et al. Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome. , 2009, Cancer research.
[17] M. Leal,et al. Thymopoiesis in elderly human is associated with systemic inflammatory status , 2009, AGE.
[18] D. Venzon,et al. Administration of rhIL-7 in humans increases in vivo TCR repertoire diversity by preferential expansion of naive T cell subsets , 2008, The Journal of experimental medicine.
[19] W. Tan,et al. Functional polymorphisms in FAS and FASL contribute to increased apoptosis of tumor infiltration lymphocytes and risk of breast cancer , 2006 .
[20] Alison A Motsinger,et al. Immunogenetics of CD4 lymphocyte count recovery during antiretroviral therapy: An AIDS Clinical Trials Group study. , 2006, The Journal of infectious diseases.
[21] T. Gingeras,et al. CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells , 2006, The Journal of experimental medicine.
[22] Howard I. Grossman. AIDS at 25: a quarter century of medical miracles. , 2006, MedGenMed : Medscape general medicine.
[23] A. Qattan,et al. The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors. , 2006, Neoplasia.
[24] J. Blay,et al. CD4 lymphopenia as a risk factor for febrile neutropenia and early death after cytotoxic chemotherapy in adult patients with cancer , 2004, Cancer.
[25] J. Blay,et al. Dendritic Cell Infiltration and Prognosis of Early Stage Breast Cancer , 2004, Clinical Cancer Research.
[26] J. Blay,et al. Baseline and early lymphopenia predict for the risk of febrile neutropenia after chemotherapy , 2003, British Journal of Cancer.
[27] Jacques Demongeot,et al. Quantitative and Qualitative Changes in V-J α Rearrangements During Mouse Thymocytes Differentiation , 2002, The Journal of Experimental Medicine.
[28] G Rassner,et al. Metastatic pathways and time courses in the orderly progression of cutaneous melanoma , 2002, The British journal of dermatology.
[29] J. Demongeot,et al. Quantitative and qualitative changes in V-J alpha rearrangements during mouse thymocytes differentiation: implication for a limited T cell receptor alpha chain repertoire. , 2002, The Journal of experimental medicine.
[30] J. Blay,et al. Identification of patients at risk for early death after conventional chemotherapy in solid tumours and lymphomas , 2001, British Journal of Cancer.
[31] M. Lotze,et al. Decreased zeta chain expression and apoptosis in CD3+ peripheral blood T lymphocytes of patients with melanoma. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[32] D. Schatz,et al. Factors and forces controlling V(D)J recombination. , 2001, Advances in immunology.
[33] J. Blay,et al. Inhibition of the differentiation of dendritic cells from CD34(+) progenitors by tumor cells: role of interleukin-6 and macrophage colony-stimulating factor. , 1998, Blood.
[34] C. Copie-Bergman,et al. CD3 hyporesponsiveness and in vitro apoptosis are features of T cells from both malignant and nonmalignant secondary lymphoid organs. , 1998, The Journal of clinical investigation.
[35] J. Blay,et al. A risk model for thrombocytopenia requiring platelet transfusion after cytotoxic chemotherapy. , 1998, Blood.
[36] C. Katlama,et al. Perturbation of CD4+ and CD8+ T-cell repertoires during progression to AIDS and regulation of the CD4+ repertoire during antiviral therapy , 1998, Nature Medicine.
[37] C. Mackall,et al. Constraints on CD4 recovery postchemotherapy in adults: thymic insufficiency and apoptotic decline of expanded peripheral CD4 cells. , 1997, Blood.
[38] J. Blay,et al. Early lymphopenia after cytotoxic chemotherapy as a risk factor for febrile neutropenia. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[39] P. Rosenberg,et al. Determining the value of additional surrogate exposure data for improving the estimate of an odds ratio. , 1995, Statistics in medicine.
[40] A. Shad,et al. Lymphocyte depletion during treatment with intensive chemotherapy for cancer. , 1994, Blood.
[41] C. C. Chen,et al. The bootstrap and identification of prognostic factors via Cox's proportional hazards regression model. , 1985, Statistics in medicine.
[42] S. Tonegawa,et al. Somatic generation of antibody diversity. , 1976, Nature.